APEIRON Strengthens Management Board
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
APEIRON Biologics AG appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth.
APEIRON Biologics AG announced the appointment of Peter Llewellyn-Davies as Chief Financial Officer and Chief Business Officer. With more than 25 years of experience in initial public offerings (IPOs), mergers & acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, the German-British national is considered one of the most experienced financial managers in the industry. During the course of his career, Llewellyn-Davies supported the successful strategic shift of Medigene AG to an immunotherapy company as well as the Munich-based Wilex AG during its IPO and several subsequent follow-on financings. Recently, Llewellyn-Davies ran his consulting firm, Accellerate Partners, and served as a Supervisory Board member for various international biotech companies.
The Chairman of APEIRON’s Supervisory Board, Dr. Manfred Reichl, welcomes the new executive: “With the tailwind of marketing approval of our new oncology product, 'Dinutuximab beta Apeiron', a new chapter is beginning for APEIRON. With Peter, we have found an ideal Chief Financial Officer who has the right experience and industry acumen to develop APEIRON into a sustainably successful biotechnology company.”
Dr. Hans Loibner, Chief Executive Officer of APEIRON, is also enthusiastic about working with Llewellyn-Davies: “Peter joins APEIRON at a decisive phase in our corporate development. As the result of our latest achievements, APEIRON has secured a good starting position for a new phase of growth. Peter´s expertise, which has been proven by many international capital market transactions, is highly welcome, and he is an ideal addition to support our growth strategy. I very much look forward to working hand in hand with him.”
Llewellyn-Davies commented: "APEIRON is currently amongst the most compelling privately owned European biotech companies. Cancer immunotherapy is an enormously promising field in which the company is well positioned due to its innovative programs. With APEIRON’s great potential in this sector, creating a strong base in the capital markets for the company represents an exciting opportunity. I am looking forward to working together with the team to jointly lead APEIRON through the next phase of growth.”
With the appointment of Llewellyn-Davies, the Supervisory and Management Boards thanked Mr. Lukas Kadawy who successfully managed the company´s financial role since inception over a period of 12 years. He played a central role in closing several financing rounds as well as large licensing agreements. In addition, he significantly contributed to obtaining the approval for 'Dinutuximab beta Apeiron'. Mr. Kadawy left the company at his own request at the end of 2015 but maintained his position on an interim basis until the hand-over to his successor. He will continue to work for and be affiliated with APEIRON in a consulting capacity and as a shareholder.
APEIRON Biologics AG announced the appointment of Peter Llewellyn-Davies as Chief Financial Officer and Chief Business Officer. With more than 25 years of experience in initial public offerings (IPOs), mergers & acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, the German-British national is considered one of the most experienced financial managers in the industry. During the course of his career, Llewellyn-Davies supported the successful strategic shift of Medigene AG to an immunotherapy company as well as the Munich-based Wilex AG during its IPO and several subsequent follow-on financings. Recently, Llewellyn-Davies ran his consulting firm, Accellerate Partners, and served as a Supervisory Board member for various international biotech companies.
The Chairman of APEIRON’s Supervisory Board, Dr. Manfred Reichl, welcomes the new executive: “With the tailwind of marketing approval of our new oncology product, 'Dinutuximab beta Apeiron', a new chapter is beginning for APEIRON. With Peter, we have found an ideal Chief Financial Officer who has the right experience and industry acumen to develop APEIRON into a sustainably successful biotechnology company.”
Dr. Hans Loibner, Chief Executive Officer of APEIRON, is also enthusiastic about working with Llewellyn-Davies: “Peter joins APEIRON at a decisive phase in our corporate development. As the result of our latest achievements, APEIRON has secured a good starting position for a new phase of growth. Peter´s expertise, which has been proven by many international capital market transactions, is highly welcome, and he is an ideal addition to support our growth strategy. I very much look forward to working hand in hand with him.”
Llewellyn-Davies commented: "APEIRON is currently amongst the most compelling privately owned European biotech companies. Cancer immunotherapy is an enormously promising field in which the company is well positioned due to its innovative programs. With APEIRON’s great potential in this sector, creating a strong base in the capital markets for the company represents an exciting opportunity. I am looking forward to working together with the team to jointly lead APEIRON through the next phase of growth.”
With the appointment of Llewellyn-Davies, the Supervisory and Management Boards thanked Mr. Lukas Kadawy who successfully managed the company´s financial role since inception over a period of 12 years. He played a central role in closing several financing rounds as well as large licensing agreements. In addition, he significantly contributed to obtaining the approval for 'Dinutuximab beta Apeiron'. Mr. Kadawy left the company at his own request at the end of 2015 but maintained his position on an interim basis until the hand-over to his successor. He will continue to work for and be affiliated with APEIRON in a consulting capacity and as a shareholder.
